Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 2
1983 2
1984 1
1985 3
1986 6
1987 1
1988 6
1989 11
1990 8
1991 23
1992 34
1993 59
1994 114
1995 83
1996 95
1997 75
1998 72
1999 85
2000 79
2001 62
2002 86
2003 77
2004 104
2005 71
2006 74
2007 63
2008 58
2009 76
2010 98
2011 100
2012 81
2013 74
2014 77
2015 87
2016 65
2017 82
2018 91
2019 104
2020 144
2021 177
2022 189
2023 156
2024 128
2025 139

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,968 results

Results by year

Filters applied: . Clear all
Page 1
Cladribine (2-chlorodeoxyadenosine).
Beutler E. Beutler E. Lancet. 1992 Oct 17;340(8825):952-6. doi: 10.1016/0140-6736(92)92826-2. Lancet. 1992. PMID: 1357355 Review. No abstract available.
2-Chlorodeoxyadenosine in haematological malignancies.
Castaigne S. Castaigne S. Nouv Rev Fr Hematol (1978). 1993 Feb;35(1):13-4. Nouv Rev Fr Hematol (1978). 1993. PMID: 8099730 Review.
This occurs because of the accumulation of deoxyadenosine nucleotides. 2-chlorodeoxyadenosine (2CdA) resists the action of adenosine deaminase and accumulates in cells. ...
This occurs because of the accumulation of deoxyadenosine nucleotides. 2-chlorodeoxyadenosine (2CdA) resists the action of ade …
2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells.
Aybar F, Julia Perez M, Silvina Marcora M, Eugenia Samman M, Marrodan M, María Pasquini J, Correale J. Aybar F, et al. Int Immunopharmacol. 2022 Apr;105:108571. doi: 10.1016/j.intimp.2022.108571. Epub 2022 Jan 29. Int Immunopharmacol. 2022. PMID: 35093689
Cladribine (2CdA) is a synthetic chlorinated purine nucleoside analogue which acts as a pro-drug requiring intracellular phosphorylation to be activated. ...
Cladribine (2CdA) is a synthetic chlorinated purine nucleoside analogue which acts as a pro-drug requiring intracellular phosphorylat …
2-Chlorodeoxyadenosine treatment of Waldenstrom's macroglobulinemia--the analysis of own experience and the review of literature.
Lewandowski K, Zaucha JM, Bieniaszewska M, Hałaburda K, Hellmann A. Lewandowski K, et al. Med Sci Monit. 2000 Jul-Aug;6(4):740-5. Med Sci Monit. 2000. PMID: 11208402 Free article. Review.
INTRODUCTION: The aim of the study was to evaluate the results of treatment of Waldenstrom's Macroglobulinemia with 2-chlorodeoxyadenosine. The evaluation was based on our own experience as well as on the data published previously in the literature. MATERIAL AND MET …
INTRODUCTION: The aim of the study was to evaluate the results of treatment of Waldenstrom's Macroglobulinemia with 2-chlorodeoxya …
2-Chlorodeoxyadenosine.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1992 Oct;9(4):192-3. doi: 10.1177/104345429200900407. J Pediatr Oncol Nurs. 1992. PMID: 1362883 No abstract available.
2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies.
Saven A, Piro LD. Saven A, et al. Ann Intern Med. 1994 May 1;120(9):784-91. doi: 10.7326/0003-4819-120-9-199405010-00010. Ann Intern Med. 1994. PMID: 7908507 Review.
OBJECTIVE: To review the structure, mechanism of action, pharmacologic features, and clinical trial results of the newer purine analog, 2-chlorodeoxyadenosine (2-CdA). DATA SOURCES AND STUDY SELECTION: English-language medical literature review of more than 70 artic …
OBJECTIVE: To review the structure, mechanism of action, pharmacologic features, and clinical trial results of the newer purine analog, 2 …
2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
Saven A, Piro LD. Saven A, et al. Hematol Cell Ther. 1996 Dec;38 Suppl 2:S93-101. Hematol Cell Ther. 1996. PMID: 9137962 Review.
2-Chlorodeoxyadenosine (2-CdA) is unique compared with traditional antimetabolites in that it is equally active against dividing and resting lymphocytes, which may be especially important in the treatment of indolent lymphoproliferative disorders because most cells …
2-Chlorodeoxyadenosine (2-CdA) is unique compared with traditional antimetabolites in that it is equally active against dividi …
2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. Weber DM, et al. Semin Oncol. 2003 Apr;30(2):243-7. doi: 10.1053/sonc.2003.50070. Semin Oncol. 2003. PMID: 12720145
Treatment for Waldenstrom's macroglobulinemia (WM) has usually been reserved for symptomatic patients and has included alkylating agent-steroid combinations and, more recently, nucleoside analogues. We now describe our experience with 2-chlorodeoxyadenosine (2-CdA) …
Treatment for Waldenstrom's macroglobulinemia (WM) has usually been reserved for symptomatic patients and has included alkylating agent-ster …
2,968 results